검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | IMiD treatment |
Overview Company | Sung-Soo Park |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which |
MoA Biomarker | biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (27 |
Clinical Primary efficacy | ORR 48.3% |
Clinical ORR | 48.3% |
Clinical Result source | ClinicalTrials.gov NCT01497496 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | IMiD treatment |
Overview Company | Sung-Soo Park |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which |
MoA Biomarker | biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (27 |
Clinical Primary efficacy | ORR 48.3% |
Clinical ORR | 48.3% |
Clinical Result source | ClinicalTrials.gov NCT01497496 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교